Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00702494

Enrollment

Registered

2008-06-20

Start date

2008-06-30

Completion date

2009-09-30

Last updated

2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Keywords

placental growth factor, monoclonal antibody, Phase I, solid tumors, Patients with solid tumors

Brief summary

TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented. In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.

Interventions

BIOLOGICALTB-403

Multiple IV

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed malignity * Measurable disease * Performance status 1 or less (ECOG)

Exclusion criteria

* Acute illness or infection * Concurrent second malignancy

Design outcomes

Primary

Measure	Time frame
Safety and tolerability of an anti-PlGF antibody	85 days

Secondary

Measure	Time frame
Determine multiple dose IV pharmacokinetics	85 days

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026